Mucins and tumor resistance to chemotherapeutic drugs.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Biochimica et Biophysica Acta

• Publication date

  2014-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.bbcan.2014.04.008PMID 24785432
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TARGETING THE MUC 1-C ONCOPROTEIN DOWNREGULATES HER 2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS

  2014cited by this paper
• Functional MUC4 suppress epithelial–mesenchymal transition in lung adenocarcinoma metastasis

  2014cited by this paper
• MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway

  2014cited by this paper
• MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/β-catenin pathway and interaction with SNAIL promoter.

  2014influential reference
• MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial–mesenchymal transition

  2014influential reference
• The emerging era of pharmacogenomics: current successes, future potential, and challenges

  2014cited by this paper
• Identification and analysis of CD133(+) melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response.

  2014cited by this paper
• Comment on: Functional MUC4 suppress epithelial-mesenchymal transition in lung adenocarcinoma metastasis. Gao L, Liu J, Zhang B, Zhang H, Wang D, Zhang T, Liu Y, Wang C. Tumour Biol. 2013, in press

  2014cited by this paper
• TARGETING THE MUC1-C ONCOPROTEIN DOWNREGULATES HER2 ACTIVATION AND ABROGATES TRASTUZUMAB RESISTANCE IN BREAST CANCER CELLS

  2013cited by this paper
• Effect of MUC1 siRNA on drug resistance of gastric cancer cells to trastuzumab.

  2013cited by this paper
• Membrane-bound mucin modular domains: from structure to function.

  2013cited by this paper
• CD133 expression in osteosarcoma and derivation of CD133⁺ cells.

  2013cited by this paper
• Oncogenic MUC1-C Promotes Tamoxifen Resistance in Human Breast Cancer

  2013cited by this paper
• Mucins in pancreatic cancer and its microenvironment

  2013cited by this paper
• Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer.

  2013cited by this paper
• Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells

  2013cited by this paper
• MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.

  2013cited by this paper
• Mucus as a barrier to lipophilic drugs.

  2013cited by this paper
• The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer.

  2013cited by this paper
• ALKBH2, a novel AlkB homologue, contributes to human bladder cancer progression by regulating MUC1 expression

  2013cited by this paper
• Catecholamine-Induced β2-Adrenergic Receptor Activation Mediates Desensitization of Gastric Cancer Cells to Trastuzumab by Upregulating MUC4 Expression

  2013cited by this paper
• Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions.

  2013cited by this paper
• MUC1-C Oncoprotein Activates ERK→C/EBPβ Signaling and Induction of Aldehyde Dehydrogenase 1A1 in Breast Cancer Cells*

  2013cited by this paper
• Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs.

  2013cited by this paper
• Mucin-type O-Glycosylation during Development*

  2013cited by this paper
• Chemoresistance Is Associated with MUC1 and Lewis y Antigen Expression in Ovarian Epithelial Cancers

  2013influential reference
• SNAI1-Mediated Epithelial-Mesenchymal Transition Confers Chemoresistance and Cellular Plasticity by Regulating Genes Involved in Cell Death and Stem Cell Maintenance

  2013cited by this paper
• Increased Understanding of the Biochemistry and Biosynthesis of MUC2 and Other Gel-Forming Mucins Through the Recombinant Expression of Their Protein Domains

  2013cited by this paper
• The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family

  2013cited by this paper
• Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer.

  2013cited by this paper
• MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes

  2013influential reference
• Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies

  2012cited by this paper
• Clonal evolution in cancer

  2012cited by this paper
• Assessing mucin expression and function in human ocular surface epithelia in vivo and in vitro.

  2012cited by this paper
• Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.

  2012cited by this paper
• Clinical implications of acellular mucin pools in resected rectal cancer with pathological complete response to neoadjuvant chemoradiation 1

  2012cited by this paper
• Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels.

  2012cited by this paper
• The Mucin MUC4 and Its Membrane Partner ErbB2 Regulate Biological Properties of Human CAPAN-2 Pancreatic Cancer Cells via Different Signalling Pathways

  2012cited by this paper
• Reversal of Paclitaxel Resistance in Epithelial Ovarian Carcinoma Cells by a MUC1 Aptamer-let-7i Chimera

  2012cited by this paper
• Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer.

  2012cited by this paper
• Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation

  2012cited by this paper
• Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers

  2012cited by this paper
• Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation.

  2012cited by this paper
• The MUC1-C Oncoprotein Binds to the BH3 Domain of the Pro-apoptotic BAX Protein and Blocks BAX Function*

  2012cited by this paper
• MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells

  2012cited by this paper
• Perspectives on mucus properties and formation--lessons from the biochemical world.

  2012cited by this paper
• Gel-forming and cell-associated mucins: preparation for structural and functional studies.

  2012cited by this paper
• The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics.

  2012cited by this paper
• MUC5B Leads to Aggressive Behavior of Breast Cancer MCF7 Cells

  2012cited by this paper
• A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer.

  2011cited by this paper
• Deconstructing the mechanisms and consequences of TGF-β-induced EMT during cancer progression

  2011cited by this paper
• Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs

  2011cited by this paper
• MUC4 gene polymorphisms associate with endometriosis development and endometriosis-related infertility

  2011cited by this paper
• Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC)

  2011cited by this paper
• Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer

  2011cited by this paper
• MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer

  2011cited by this paper
• Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells

  2011cited by this paper
• Mucin 13: Structure, Function, and Potential Roles in Cancer Pathogenesis

  2011cited by this paper
• MUC13 Mucin Augments Pancreatic Tumorigenesis

  2011cited by this paper
• Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine

  2011cited by this paper
• MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells

  2011influential reference
• Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer.

  2011cited by this paper
• The Impact of Perioperative Chemotherapy on Survival in Patients With Gastric Signet Ring Cell Adenocarcinoma: A Multicenter Comparative Study

  2011cited by this paper
• Significance of Acellular Mucin Pools in Rectal Carcinoma After Neoadjuvant Chemoradiotherapy

  2011cited by this paper
• Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells

  2011cited by this paper
• Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer.

  2010cited by this paper
• Effects of Thymoquinone in the Expression of Mucin 4 in Pancreatic Cancer Cells: Implications for the Development of Novel Cancer Therapies

  2010cited by this paper
• MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition

  2010cited by this paper
• Survival of Human Multiple Myeloma Cells Is Dependent on MUC1 C-Terminal Transmembrane Subunit Oncoprotein Function

  2010cited by this paper
• MUC1 immunotherapy.

  2010cited by this paper
• RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells

  2010cited by this paper
• Mucins and Pancreatic Cancer

  2010cited by this paper
• MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells

  2010cited by this paper
• MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells

  2010cited by this paper
• Clinical Significance of Acellular Mucin in Rectal Adenocarcinoma Patients With a Pathologic Complete Response to Preoperative Chemoradiation

  2010cited by this paper
• MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.

  2010influential reference
• Pathologic Response Rate After Concomitant Neo-Adjuvant Radiotherapy and Chemotherapy for Adenocarcinoma of the Uterine Cervix: A Retrospective Multicentric Study

  2010cited by this paper
• Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells

  2010influential reference
• Clonal evolution in cancer

  2010cited by this paper
• RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells

  2010cited by this paper
• The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers.

  2010cited by this paper
• The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms.

  2009cited by this paper
• MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells

  2009cited by this paper
• Epithelial-mesenchymal transitions in development and disease.

  2009cited by this paper
• Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic.

  2009cited by this paper
• ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumor cells induced by truncated MUC1.

  2009cited by this paper
• Mucins in cancer: function, prognosis and therapy

  2009cited by this paper
• Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours.

  2009influential reference
• MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment

  2009cited by this paper
• Identification of selective inhibitors of cancer stem cells by high-throughput screening.

  2009cited by this paper
• Mucin CYS domains are ancient and highly conserved modules that evolved in concert.

  2009cited by this paper
• Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin

  2009cited by this paper
• MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression.

  2009cited by this paper
• A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development

  2009cited by this paper
• Architecture of the large membrane-bound mucins.

  2008cited by this paper
• The membrane-bound mucins: how large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies.

  2008cited by this paper
• ABC multidrug transporters: structure, function and role in chemoresistance.

  2008cited by this paper
• Persistence of side population cells with high drug efflux capacity in pancreatic cancer.

  2008cited by this paper
• Reactive oxygen species: Current knowledge and applications in cancer research and therapeutic

  2008cited by this paper
• Structure and function of the polymeric mucins in airways mucus.

  2008cited by this paper

• Establishment of endogenous canine MUC1 knock-out MDCKII cells using CRISPR-Cas9 and evaluation of drug permeation.

  2025cites this paper
• Unraveling the role of mucins and gut microbiota in gastrointestinal cancers chemoresistance.

  2025cites this paper
• Mucin-Targeted Antibodies for Ovarian Cancer.

  2025cites this paper
• Comparative Outcomes of Neo-Adjuvant Chemo-Radiotherapy in Stage II and III Mucinous versus Non-Mucinous Rectal Adenocarcinoma: A Retrospective Study

  2025cites this paper
• Tcf4 regulates secretory cell fate decisions in the small intestine and colon tumors: insights from transcriptomic, histological, and microbiome analyses

  2025cites this paper
• Patient-derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas.

  2025cites this paper
• Up-Regulation of Non-Homologous End-Joining by MUC1

  2024cites this paper
• Mucins as Precision Biomarkers in Glioma: Emerging Evidence for Their Potential in Biospecimen Analysis and Outcome Prediction

  2024influential citation
• RUNX1-MUC13 Interaction Activates Wnt/β-Catenin Signaling Implications for Colorectal Cancer Metastasis

  2024cites this paper
• Transcriptomic Landscape of Colorectal Mucinous Adenocarcinoma has Similarity with Intestinal Goblet Cell Differentiation

  2024cites this paper
• Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance

  2024cites this paper
• Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation

  2023cites this paper
• Altered Glycosylation in Progression and Management of Bladder Cancer

  2023cites this paper
• Mucins and mucinous ovarian carcinoma: Development, differential diagnosis, and treatment

  2023influential citation
• A Novel NCI-H69AR Drug-Resistant Small-Cell Lung Cancer Mini-Tumor Model for Anti-Cancer Treatment Screening

  2023cites this paper
• Bromelain and acetylcysteine (BromAc®): a novel approach to the treatment of mucinous tumours.

  2023cites this paper
• Design of a mucin-selective protease for targeted degradation of cancer-associated mucins

  2022cites this paper
• Possible Therapeutics for Pseudomyxoma Peritonei: A Rare, Lethal, and the Least Investigated Disease

  2022cites this paper
• MUC13-miRNA-4647 axis in colorectal cancer: Prospects to identifications of risk factors and clinical outcomes

  2022cites this paper
• Cancer antigen 125 expression enhances the gemcitabine/cisplatin-resistant tumor microenvironment in bladder cancer.

  2022cites this paper
• Molecular Classification of Appendiceal Adenocarcinoma

  2022cites this paper
• The Glycosylated N-Terminal Domain of MUC1 Is Involved in Chemoresistance by Modulating Drug Permeation Across the Plasma Membrane

  2022influential citation
• Mucin 13 (MUC13) as a candidate biomarker for ovarian cancer detection: potential to complement CA125 in detecting non-serous subtypes

  2022cites this paper
• MUC1-mediated Macrophage Activation Promotes Colitis-associated Colorectal Cancer via Activating the Interleukin-6/ Signal Transducer and Activator of Transcription 3 Axis

  2022cites this paper
• Antibody-Based Approaches to Target Pancreatic Tumours

  2022cites this paper
• MUC1 mediated macrophage activation promotes colitis-associated colorectal cancer via activating the IL-6/STAT3 axis.

  2022cites this paper
• Current Nano-Strategies to Improve Therapeutic Efficacy Across Special Structures

  2022cites this paper
• Mucin 21 confers resistance to apoptosis in an O-glycosylation-dependent manner

  2022cites this paper
• Microbe–Mucus Interface in the Pathogenesis of Colorectal Cancer

  2021cites this paper
• Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer

  2021cites this paper
• Role of human nucleoside transporters in pancreatic cancer and chemoresistance

  2021cites this paper
• Mucin-producing hamster cholangiocarcinoma cell line, Ham-2, possesses the aggressive cancer phenotypes with liver and lung metastases

  2021cites this paper
• Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion

  2021cites this paper
• Mucinous Adenocarcinoma Predicts Poor Response and Prognosis in Patients With Locally Advanced Rectal Cancer: A Pooled Analysis of Individual Participant Data From 3 Prospective Studies.

  2021cites this paper
• Resveratrol inhibits MUC5AC expression by regulating SPDEF in lung cancer cells.

  2021cites this paper
• Mucins reprogram stemness, metabolism and promote chemoresistance during cancer progression

  2021cites this paper
• The Unique Biology behind the Early Onset of Breast Cancer

  2021cites this paper
• Synthesis, Anti-Tumor Activity and Apoptosis-Inducing Effect of Novel Dimeric Keggin-Type Phosphotungstate

  2021cites this paper
• Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance

  2020cites this paper
• EGF-containing Membrane-bound Mucins: a hidden ErbB2 targeting pathway?

  2020cites this paper
• MiR-BART1-5p targets core 2β-1,6-acetylglucosaminyltransferase GCNT3 to inhibit cell proliferation and migration in EBV-associated gastric cancer.

  2020cites this paper
• Tumour Cell Secretome in Chemoresistance and Tumour Recurrence.

  2020cites this paper
• Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells In Vitro

  2020cites this paper
• Tepotinib Inhibits the Epithelial–Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels

  2020cites this paper
• Mucins in pancreatic cancer: A well‐established but promising family for diagnosis, prognosis and therapy

  2020cites this paper
• Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer.

  2020cites this paper
• Chemo-sensitizing agents from natural origin for colorectal cancer: Pharmacodynamic and cellular pharmacokinetics approaches

  2020cites this paper
• Single-Cell Analysis May Shed New Lights on the Role of LncRNAs in Chemoresistance in Gastrointestinal Cancers

  2020cites this paper
• MUC glycoproteins: Potential biomarkers and molecular targets for cancer therapy.

  2020cites this paper
• Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer

  2019cites this paper
• A novel treatment of bromelain and acetylcysteine (BromAc) in patients with peritoneal mucinous tumours: A phase I first in man study.

  2019cites this paper
• Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response

  2019cites this paper
• Redox-Responsive Disulfide Bond-Bridged mPEG-PBLA Prodrug Micelles for Enhanced Paclitaxel Biosafety and Antitumor Efficacy

  2019cites this paper
• MUC13 promotes the development of colitis-associated colorectal tumors via β-catenin activity

  2019cites this paper
• The "nano to micro" transition of hydrophobic curcumin crystals leading to in situ adjuvant depots for Au-liposome nanoparticle mediated enhanced photothermal therapy.

  2019cites this paper
• Bacterial biofilms as a potential contributor to mucinous colorectal cancer formation.

  2019cites this paper
• The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma.

  2019cites this paper
• Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma

  2019cites this paper
• High expression of MUC20 drives tumorigenesis and predicts poor survival in endometrial cancer

  2019cites this paper
• Mucin glycoproteins block apoptosis; promote invasion, proliferation, and migration; and cause chemoresistance through diverse pathways in epithelial cancers

  2019cites this paper
• Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs

  2019cites this paper
• Mucin 2 (MUC2) modulates the aggressiveness of breast cancer

  2018cites this paper
• Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles

  2018cites this paper
• The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance

  2018cites this paper
• Recent Insights into Mucinous Ovarian Carcinoma

  2018cites this paper
• The effect of hyperthermia (42°C) on the anti-tumoral effect of bromelain, N-acetyl cysteine, chemotherapeutic agents and their combinations - an in vitro evaluation

  2018cites this paper
• Axed MUC4 (MUC4/X) aggravates pancreatic malignant phenotype by activating integrin-β1/FAK/ERK pathway.

  2018cites this paper
• New Treatment Modalities for the Management of Peritoneal Metastases

  2018cites this paper
• Sarcosine influences apoptosis and growth of prostate cells via cell‐type specific regulation of distinct sets of genes

  2018cites this paper
• Autocrine mechanisms of cancer chemoresistance.

  2017cites this paper
• Is mucin a determinant of peritoneal dissemination of gastrointestinal cancer? Analysis of mucin depletion in two preclinical models

  2017cites this paper
• Mucin 4 detection with a label-free electrochemical immunosensor

  2017cites this paper
• Targeting MUC16 in Cancer Therapy

  2017cites this paper
• MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance

  2017cites this paper
• The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting.

  2017cites this paper
• Depletion of MUC5B mucin in gastrointestinal cancer cells alters their tumorigenic properties: implication of the Wnt/β-catenin pathway.

  2017cites this paper
• Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy.

  2017influential citation
• Mucins and Tumor Biology

  2016cites this paper
• Light-Induced Hydrogel Based on Tumor-Targeting Mesoporous Silica Nanoparticles as a Theranostic Platform for Sustained Cancer Treatment.

  2016cites this paper
• MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells.

  2016cites this paper
• MUC5AC interactions with integrin β4 enhances the migration of lung cancer cells through FAK signaling

  2016cites this paper
• A Novel Approach to Peritoneal Dissemination of Mucin-Expressing Malignancies of Gastrointestinal Origin

  2016cites this paper
• Molecular Pathways: Mucins and Drug Delivery in Cancer

  2016cites this paper
• Expression of MUC15 and PI3K/Akt in gastric carcinoma and its association with clini- copathological characteristics and prognosis

  2016cites this paper
• MUC13 protects colorectal cancer cells from death by activating the NF-κB pathway and is a potential therapeutic target

  2016cites this paper
• Small-Molecule Inhibition of GCNT3 Disrupts Mucin Biosynthesis and Malignant Cellular Behaviors in Pancreatic Cancer.

  2016cites this paper
• Potentiation of chemotherapeutics by bromelain and N-acetylcysteine: sequential and combination therapy of gastrointestinal cancer cells.

  2016cites this paper
• Self-templated formation of aptamer-functionalized copper oxide nanorods with intrinsic peroxidase catalytic activity for protein and tumor cell detection

  2016cites this paper
• Structural characterization of a Vatairea macrocarpa lectin in complex with a tumor-associated antigen: A new tool for cancer research.

  2016cites this paper
• Preparation and antitumor effect evaluation of composite microparticles co-loaded with siRNA and paclitaxel by a supercritical process.

  2015cites this paper
• Depletion of mucin in mucin-producing human gastrointestinal carcinoma: Results from in vitro and in vivo studies with bromelain and N-acetylcysteine

  2015cites this paper
• Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer.

  2015cites this paper
• Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma

  2015cites this paper
• Targeting MUC4 in pancreatic cancer: miRNAs

  2015cites this paper
• Multifunctional gold nanorods for selective plasmonic photothermal therapy in pancreatic cancer cells using ultra-short pulse near-infrared laser irradiation.

  2015cites this paper